Stavudine-based multiple agent combinations: Initial studies and ongoing comparative trials

Robert Leo Murphy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Initial studies of multiple-agent antiretroviral combinations including the thymidine nucleoside analogue reverse transcriptase inhibitor (RTI) stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T) have shown potent anti-HIV effects in both treatment-naive and -experienced patients. A number of ongoing randomized comparative trials are assessing stavudine-based multiple agent combinations, including protease inhibitor-containing and -sparing regimens, triple nucleoside RTI regimens and regimens including non-nucleoside RTIs and/or hydroxyurea as initial or subsequent therapy. Results of these studies should help to define additional first-line treatment options and strategies for sequencing antiretroviral treatment regimens.

Original languageEnglish (US)
Pages (from-to)69-73
Number of pages5
JournalAntiviral Therapy
Volume3
Issue numberSUPPL. 4
StatePublished - Dec 23 1998

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Stavudine-based multiple agent combinations: Initial studies and ongoing comparative trials'. Together they form a unique fingerprint.

Cite this